Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099554
Status:
COMPLETED
Last Update Posted:
2009-11-13
First Post:
2004-12-16
Brief Title:
Effectiveness and Safety of Enbrel Etanercept in Rheumatoid Arthritis Subjects Who Have Failed Remicade Infliximab
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 4 Open-Label Single Arm Observational Study Evaluating the Effectiveness and Safety of Enbrel Etanercept 50 mg Once Weekly in Rheumatoid Arthritis Subjects Who Have Failed Remicade Infliximab
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the proportion of Rheumatoid Arthritis RA subjects achieving a good or moderate DAS28 response EULAR28 criteria at Week 16 with etanercept 50 mg subcutaneously SC once weekly in patients who have failed infliximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None